Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab Maintenance After Allo-SCT for Relapsed/Refractory Multiple Myeloma
NCT04024384Phase 2Withdrawn
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jul 2019
- Primary completion
- Jul 2024
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daratumumab in multiple myeloma (MM), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Progression-Free Survival at 12 months. Planned start Jul 2019; status: withdrawn.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04024384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04024384.